hfpef tirzepatide SUMMIT: Improves Outcomes and Quality of Life For Patients With and Obesity Tirzepatide and Cardiovascular Outcomes: A

Ozempic is manufactured by Novo Nordisk, a Danish pharmaceutical company that pioneered GLP-1 receptor agonist therapy

Discover how weight loss from Ozempic impacts musculoskeletal health

MacCloud supervises your protocol at ARTC.

The dual incretin agonist tirzepatide reduced 24-hour ambulatory BP for adults with obesity-related hypertension, with the effects potentially independent of weight loss, according to data from a planned substudy of the SURMOUNT-1 trial.“Tirzepatide led to clinically meaningful reductions in ambulatory blood pressure among adults with overweight and obesity, with reductions in the range

About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds.

Learn how berberine may aid weight loss, dosage, and why its gaining popularity as a natural alternative